Vanguard Group Inc. Boosts Holdings in Alphatec Holdings, Inc. $ATEC

Key Points

• Vanguard Group Inc. has increased its holdings in Alphatec Holdings, Inc. by 0.8% during the first quarter, now owning about 4.12% of the company, valued at approximately $60.99 million.
• Alphatec stock recently traded up 1.3% to $16.05, with a market cap of $2.38 billion and a reported revenue of $185.54 million for its last quarter, representing a 27.5% year-over-year growth.
• Recent research reports have set new price targets for Alphatec, with Barclays reaffirming an “overweight” rating and raising its price objective to $22.00, while the average price target among analysts stands at $18.50.

Vanguard Group Inc. lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 0.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,014,772 shares of the medical technology company's stock after purchasing an additional 45,792 shares during the period. Vanguard Group Inc. owned about 4.12% of Alphatec worth $60,990,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Comerica Bank raised its position in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares during the last quarter. Quarry LP grew its holdings in Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after acquiring an additional 2,375 shares in the last quarter. Larson Financial Group LLC acquired a new position in Alphatec during the 1st quarter worth approximately $54,000. Lazard Asset Management LLC acquired a new position in shares of Alphatec in the 4th quarter valued at $76,000. Finally, State of Wyoming purchased a new stake in Alphatec in the 4th quarter valued at $86,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ATEC has been the subject of a number of research analyst reports. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Piper Sandler reissued an "overweight" rating and issued a $15.00 price objective (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Barclays reaffirmed an "overweight" rating and set a $22.00 price target (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research note on Monday, June 16th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $18.50.

Insider Activity at Alphatec

In related news, General Counsel Tyson Eliot Marshall sold 18,092 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the transaction, the general counsel owned 438,331 shares in the company, valued at approximately $6,535,515.21. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Craig E. Hunsaker sold 186,122 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total transaction of $2,296,745.48. Following the completion of the transaction, the executive vice president owned 1,463,896 shares in the company, valued at $18,064,476.64. The trade was a 11.28% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 410,247 shares of company stock worth $5,376,804. Company insiders own 20.90% of the company's stock.

Alphatec Trading Down 1.0%

NASDAQ:ATEC traded down $0.16 during trading hours on Thursday, reaching $16.03. 1,095,072 shares of the company were exchanged, compared to its average volume of 2,057,853. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -14.18 and a beta of 1.05. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $16.47. The stock has a 50 day simple moving average of $12.68 and a 200 day simple moving average of $11.66.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The company had revenue of $185.54 million for the quarter, compared to the consensus estimate of $178.85 million. During the same quarter last year, the firm posted ($0.29) earnings per share. Alphatec's revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. As a group, analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.